B12/CRP指数作为晚期癌症患者的一个简单预后指标：一项验证性研究。
The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study.
作者信息
Kelly L, White S, Stone P C
机构信息
Palliative Medicine, Surrey and Sussex Healthcare NHS Trust, Surrey, UK.
出版信息
Ann Oncol. 2007 Aug;18(8):1395-9. doi: 10.1093/annonc/mdm138. Epub 2007 May 19.
BACKGROUND
The vitamin B(12)/C-reactive protein Index (BCI) has been proposed as a prognostic indicator in patients with advanced cancer. The purpose of this study was to confirm the utility of the BCI in palliative care patients.
PATIENTS AND METHODS
Patients with advanced cancer provided a blood specimen for analysis. Demographic and disease-related variables were recorded. Patients were followed up for at least 90 days or until death.
RESULTS
Patients (n = 329) were divided into three groups according to their BCI score. Patients in group 3 (BCI >40,000; median survival 29 days) had a significantly (P < 0.01) worse survival than patients in group 2 (BCI 10,001-40,000; median survival 43 days) and patients in group 1 (BCI < or =10,000; median survival 71 days). However, patients in group 1 did not have a significantly better prognosis than those in group 2 (P = 0.091). The point estimates for 90-day mortality for each of the three risk groups were different from the figures previously reported during the development phase of the BCI (group 1, 58.9% versus 47.2%; group 2, 64.0 versus 72.5%; group 3, 78.9% versus 90.6%).
CONCLUSIONS
An elevated BCI (>40,000) predicts poor survival in patients with advanced cancer.
背景
维生素B12/ C反应蛋白指数（BCI）已被提议作为晚期癌症患者的预后指标。本研究的目的是证实BCI在姑息治疗患者中的实用性。
患者与方法
晚期癌症患者提供血样进行分析。记录人口统计学和疾病相关变量。对患者进行至少90天的随访或直至死亡。
结果
根据BCI评分将患者（n = 329）分为三组。第3组患者（BCI> 40,000；中位生存期29天）的生存期明显（P <0.01）差于第2组患者（BCI 10,001 - 40,000；中位生存期43天）和第1组患者（BCI≤10,000；中位生存期71天）。然而，第1组患者的预后并不比第2组患者明显更好（P = 0.091）。三个风险组各自的90天死亡率的点估计值与BCI开发阶段先前报告的数字不同（第1组，58.9%对47.2%；第2组，64.0对72.5%；第3组，78.9%对90.6%）。
结论
BCI升高（> 40,000）预示晚期癌症患者生存期较差。
Zotero 插件